Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
BUR's Cash to Debt is ranked higher than
99% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. BUR: No Debt )
BUR' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.84
BUR's Equity to Asset is ranked higher than
87% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. BUR: 0.84 )
BUR' s 10-Year Equity to Asset Range
Min: 0.84   Max: 0.93
Current: 0.84

0.84
0.93
Interest Coverage No Debt
BUR's Interest Coverage is ranked higher than
89% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BUR: No Debt )
BUR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 77.99
M-Score: -1.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6582.11
BUR's Operating margin (%) is ranked higher than
51% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. BUR: -6582.11 )
BUR' s 10-Year Operating margin (%) Range
Min: -18770   Max: -6582.11
Current: -6582.11

-18770
-6582.11
Net-margin (%) -6275.79
BUR's Net-margin (%) is ranked higher than
51% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. BUR: -6275.79 )
BUR' s 10-Year Net-margin (%) Range
Min: -18486.67   Max: -6275.79
Current: -6275.79

-18486.67
-6275.79
ROE (%) -137.91
BUR's ROE (%) is ranked higher than
53% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. BUR: -137.91 )
BUR' s 10-Year ROE (%) Range
Min: -137.91   Max: -1.93
Current: -137.91

-137.91
-1.93
ROA (%) -116.38
BUR's ROA (%) is ranked higher than
51% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. BUR: -116.38 )
BUR' s 10-Year ROA (%) Range
Min: -116.38   Max: -1.88
Current: -116.38

-116.38
-1.88
ROC (Joel Greenblatt) (%) -941.72
BUR's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. BUR: -941.72 )
BUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1220.33   Max: -187.78
Current: -941.72

-1220.33
-187.78
EBITDA Growth (%) -15.70
BUR's EBITDA Growth (%) is ranked higher than
69% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. BUR: -15.70 )
BUR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 49.4
Current: -15.7

0
49.4
EPS Growth (%) -14.10
BUR's EPS Growth (%) is ranked higher than
72% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. BUR: -14.10 )
BUR' s 10-Year EPS Growth (%) Range
Min: -18.1   Max: 326.4
Current: -14.1

-18.1
326.4
» BUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BUR Guru Trades in Q3 2013

Chuck Royce 419,903 sh (unchged)
» More
Q4 2013

BUR Guru Trades in Q4 2013

Chuck Royce 419,903 sh (unchged)
» More
Q1 2014

BUR Guru Trades in Q1 2014

Chuck Royce 419,903 sh (unchged)
» More
Q2 2014

BUR Guru Trades in Q2 2014

Chuck Royce 433,253 sh (+3.18%)
» More
» Details

Insider Trades

Latest Guru Trades with BUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 28.21
BUR's P/B is ranked lower than
60% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. BUR: 28.21 )
BUR' s 10-Year P/B Range
Min: 0   Max: 31.3
Current: 28.21

0
31.3
EV-to-EBIT -20.29
BUR's EV-to-EBIT is ranked higher than
73% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BUR: -20.29 )
BUR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -20.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 197.50
BUR's Price/Net Cash is ranked higher than
53% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BUR: 197.50 )
BUR' s 10-Year Price/Net Cash Range
Min: 9.89   Max: 204.5
Current: 197.5

9.89
204.5
Price/Net Current Asset Value 197.50
BUR's Price/Net Current Asset Value is ranked higher than
53% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. BUR: 197.50 )
BUR' s 10-Year Price/Net Current Asset Value Range
Min: 9.89   Max: 204.5
Current: 197.5

9.89
204.5
Price/Tangible Book 39.50
BUR's Price/Tangible Book is ranked lower than
64% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. BUR: 39.50 )
BUR' s 10-Year Price/Tangible Book Range
Min: 6.59   Max: 50
Current: 39.5

6.59
50
Forward Rate of Return (Yacktman) -13.92
BUR's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. BUR: -13.92 )
BUR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -13.92

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BU.Canada, BNE.Germany
Burcon NutraScience Corporation was founded in 1998 and is headquartered in Vancouver, Canada. The company, through its subsidiary, Burcon NutraScience (MB) Corp. is a research and development company building a portfolio of composition, application and process patents around its plant protein extraction and purification technology. The company's products include CLARISOY, a soy protein isolate, which is used in various food products, including protein shakes, power bars, soups and sauces, meats and meat analogs, and breads and baked foods; and PEAZAZZ, a soluble pea protein isolate. Its products also comprise canola protein isolates, such as Supertein that comprises albumin proteins used in beverages, confectionery, aerated desserts, and protein bars; Puratein, which consists of globulin proteins used in dressings and sauces, meat substitutes, baked goods, and protein bars.
» More Articles for NAS:BUR

Headlines

Articles On GuruFocus.com
Burelle: A Growing Euro for 50 cents Mar 12 2013 

More From Other Websites
Nasdaq stocks posting largest volume increases Aug 21 2014
BURCON REPORTS FISCAL 2015 FIRST QUARTER RESULTS Aug 14 2014
Burcon Reports Fiscal 2015 First Quarter Results Aug 14 2014
3rd Annual Gateway Conference to Feature Select Group of Canadian-Listed Growth Companies on... Aug 06 2014
BURCON SETS FIRST FISCAL QUARTER 2015 CONFERENCE CALL FOR THURSDAY AUGUST 14, 2014 AT 5:00 P.M. ET Aug 05 2014
Burcon Sets First Fiscal Quarter 2015 Conference Call for Thursday August 14, 2014 at 5:00 p.m. ET Aug 05 2014
3rd Annual Gateway Conference to Showcase More Than 60 High-Growth Public Companies in San Francisco... Jul 21 2014
BURCON NUTRASCIENCE CORP Financials Jun 28 2014
Burcon Reports Fiscal Fourth Quarter and Year 2014 Results Jun 23 2014
Burcon Sets Fourth Fiscal Quarter 2014 Conference Call for June 23, 2014 at 5:00 p.m. ET Jun 10 2014
ADM ANNOUNCES INTENTION TO EXPAND COMMERCIAL PRODUCTION OF CLARISOY™ Mar 06 2014
BURCON NUTRASCIENCE TO PRESENT AT THE 26TH ANNUAL ROTH CONFERENCE ON MARCH 11, 2014 Feb 25 2014
Burcon NutraScience's Management Discusses F3Q 2014 Results - Earnings Call Transcript Feb 14 2014
BURCON RIGHTS TO COMMENCE TRADING ON FEBRUARY 14, 2014 Feb 11 2014
Liolios Group Appoints Wojtek Nowak as Managing Director of Canada Dec 17 2013
BURCON TO PRESENT AT 6TH ANNUAL LD MICRO CONFERENCE ON DECEMBER 5 Nov 20 2013
BURCON REPORTS FISCAL 2014 SECOND QUARTER RESULTS Nov 13 2013
BURCON SETS SECOND FISCAL QUARTER 2014 CONFERENCE CALL FOR WEDNESDAY, NOVEMBER 13, 2013 AT 5:00 P.M.... Oct 31 2013
Burcon NutraScience to Present at the 2013 Gateway Conference on September 10 Aug 22 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide